| Korea | Russia | Malaysia
Indonesia | All Others

eg.stem cell, stem cell treatment
Stem cell treatment | Parkinson's Disease | Multiple Sclerosis | ALS | Brain Injury | Spinal Cord Injury | Cerebaral Palsy | Batten Disease | Stroke
MSA | Muscular Dystrophy | Epilepsy | Optic neuritis | Encephalomyelitis | SMA | Huntingdon's disease | Friedrich ataxia | Diabetes
HOME > News > Article Content

Early Steps in Parkinson's Pathology Revealed


http://www.sciencedaily.com/releases/2010/04/100406125541.htm

ScienceDaily (Apr. 6, 2010)

Although the cause of Parkinson's disease remains a mystery, scientists now have a better understanding of the earliest stages of abnormal aggregation of a key disease-associated protein. The research, published online on April 6th in Biophysical Journal, provides new insight into the first steps in the formation of neurotoxic structures called Lewy bodies that are the hallmark of the Parkinson's brain.

Parkinson's disease is a neurodegenerative disorder that impairs movement and has been linked with a pathological accumulation of ¦Á-Synuclein protein inside of neurons. ¦Á-Synuclein is a small, abundant protein that is intrinsically present in a disordered or "unfolded" state but displays a remarkable structural versatility. Previous research has shown that large fibrous clumps of ¦Á-Synuclein are present in Lewy bodies in the brains of Parkinson's patients.

"¦Á-Synuclein can readily adopt different structures and, prior to formation of the large fibrous form, forms early small intermediates called oligomers," explains senior study author Dr. Yves Engelborghs from the Laboratory of Biomolecular Dynamics at the University of Leuven in Belgium. "Because the potential role of these intermediates in cell death has been established, detection and characterization of early oligomeric species is very important for understanding Parkinson's pathology."

The formation of ¦Á-Synuclein oligomers prior to the formation of larger fibrils has been shown before, but the many forms and transient nature of ¦Á-Synuclein oligomers has made identification and characterization of the amount, size and conformation of these early intermediates very difficult. Dr. Engelborghs and colleagues used a sophisticated and sensitive imaging technique called fluorescence correlation spectroscopy to follow the disappearance of individual ¦Á-Synuclein molecules (called monomers) and the formation of early oligomers during the aggregation process.
The researchers characterized the kinetics of oligomer formation and demonstrated that the formation of early oligomers was concentration dependent. Using a different technique, they went on to show that oligomer formation was accompanied by a conformational change that preceded formation of higher order structures. Taken together, the results provide new insight into the initial steps of ¦Á-Synuclein aggregation.

Researchers include Sangeeta Nath, Jessika Meuvis, Jelle Hendrix, Shaun A. Carl and Yves Engelborghs, of University of Leuven, Leuven, Belgium.

 



Related Information:

  • The Washington Post report regarding our center and specialized stem cell treatment   
  • Stem cell therapy, a promising novel endeavor for neurological disorders   
  • Major ALS breakthrough-common cause of all forms of ALS discovered   
  • Imaging Study Shows Slower Growth In Autistic Brains Extending Into Adolescence   
  • 'Pushing Limits' - New Drug Strategies For Alzheimer's, Multiple Sclerosis   
  • Study Suggests Varying Practice Sessions May Benefit People With Motor Disorders   
  • New Drug Strategies for Alzheimer's and Multiple Sclerosis   
  • Antiviral Drugs May Slow Alzheimer's Progression   
  • Precision With Stem Cells a Step Forward for Treating Multiple Sclerosis, Other Diseases   
  • Minority Children Less Likely to Receive CT Scans Following Head Trauma   
  • Reassurance for Dementia Sufferers On Impact of Common Drugs   
  • Understanding the Beginnings of Embryonic Stem Cells Helps Predict the Future   
  • By Reprogramming Skin Cells Into Brain Cells, Scientists Gain New Insights Into Mental Disorders   
  • Family History May Have More Important Role Than Previously Thought in Development of Alzheimer Disease   
  • Evidence Points to Potential Roles for Cognitive Rehabilitation Therapy in Treating Traumatic Brain Injury,   
  • New Drug Target for Alzheimer's, Stroke Discovered   
  • New Drug Target for Alzheimer's, Stroke Discovered   
  • A Safe Vaccination for Alzheimer's Disease?   
  • Think You're in Poor Health? It Could Increase Your Odds of Dementia   
  • Models of Autism Show That Gene Copy Number Controls Brain Structure and Behavior   
  • Patient-Specific Stem Cells: Major Step Toward Cell-Based Therapies for Life-Threatening Diseases   
  • One Quarter of Seniors Over 70 Have Had Silent Strokes   
  • Remitting Multiple Sclerosis: Natalizumab Reduces Relapses and Disability   
  • Seeds of Destruction in Parkinson's Disease: Spread of Diseased Proteins Kills Neurons   
  • Even High-But-Normal Blood Pressure Elevates Stroke Risk   
  • Commonly Used Supplement May Improve Recovery from Spinal Cord Injuries   
  • Key to Survival of Brain Cells Discovered   
  • Correcting Sickle Cell Disease With Stem Cells   
  • New Stem Cell Activity Identified in Human Brain   
  • New Stem Cell Activity Identified in Human Brain   
  • Treatment
    The Parkinson's Clinical Center
    Doctor Blogs
    Treatment Data
    Contact Us

  • What are stem cells and how do they work to treat various diseases?   
  • How do stem cells know where to go and what to do?   
  • What kinds of stem cells does your medical center use and are they safe?   
  • Where do the stem cells come from?   
  • Is stem cell treatment safe? Is it really effective?   
  • How do I know if I am a good candidate for stem cell therapy?   
  • How long should I expect to stay in Beijing for the treatment?   
  • Can you use adult stem cells from my own bone marrow?   
  • What methods do you use to transplant stem cells into the patient's body?   
  • What should I expect to experience during the stem cell treatment?   
  • Do the doctors use anesthesia during the operation?   
  • What other drugs does the doctor combine with the stem cells for therapy?   
  • How long after surgery will it be before I can bathe or shower?   
  • For Batten disease treatment, what type of stem cells are used?   
  • About the neural growth factors that your medical center use   
  • If your hospitals have an age restriction on patients?   
  • What medications do you use on Batten disease patients?   
  • Is it possible for you to manufacture the TPP1 enzyme and deliver it?   
  • When I send my records to your hospital, does a doctor read them?   
  • Is general anesthesia used?   
  • Is other therapy done in addition to stem cell infusion?   
  • What types of rehabilitation training is done?   
  • What will my treatment schedule be like?   
  • Does the doctor have to penetrate the spinal canal to infuse the stem cells   
  • If I have to have surgery, how long will it take for the wound to heal?   
  • Will I lose very much blood?   
  • If there is surgery, can I fly back home before the wound has healed?   
  • Does your medical center also offer conventional treatment?   
  • What is the most effective way to contact us?   
  • Are stem cells pre-tested for HIV and Hepatitis? What else do you test?   
  • Send Inquiry Contact Us Sitemap Help

    Link:Like Cell Research Center | stemcellshezhong.com
    Copyright © 2011 unistemcells.com All rights reserved.